Objective-The objective of this study was to identify the role of dimethylarginine dimethylaminohydrolase-1 (DDAH1) in degrading the endogenous nitric oxide synthase inhibitors asymmetrical dimethylarginine (ADMA) and N g -monomethyl-L-arginine (L-NMMA). Methods and Results-We generated a global-DDAH1 gene-deficient (DDAH1 Ϫ/Ϫ ) mouse strain to examine the role of DDAH1 in ADMA and L-NMMA degradation and the physiological consequences of loss of DDAH1. Plasma and tissue ADMA and L-NMMA levels in DDAH1 Ϫ/Ϫ mice were several folds higher than in wild-type mice, but growth and development of these DDAH1 Ϫ/Ϫ mice were similar to those of their wild-type littermates. Although the expression of DDAH2 was unaffected, DDAH activity was undetectable in all tissues tested. These findings indicate that DDAH1 is the critical enzyme for ADMA and L-NMMA degradation. Blood pressure was Ϸ20 mm Hg higher in the DDAH1 Ϫ/Ϫ mice than in wild-type mice, but no other cardiovascular phenotype was found under unstressed conditions. Crossing DDAH1 ϩ/Ϫ male with DDAH1 ϩ/Ϫ female mice yielded DDAH1 ϩ/ϩ , DDAH1 ϩ/Ϫ , and DDAH1 Ϫ/Ϫ mice at the anticipated ratio of 1:2:1, indicating that DDAH1 is not required for embryonic development in this strain. 3, 4 or inducing S-nitrosylation 5 to regulate protein stability and function. NO production is restrained by the endogenous nitric oxide synthase (NOS) inhibitors asymmetrical dimethylarginine (ADMA) and N g -monomethyl-L-arginine (L-NMMA). 6, 7 In intact animals, infusion of ADMA or L-NMMA increases vascular resistance and blood pressure. 1,8 Cardiovascular diseases, including hypertension, 9 coronary artery disease, 10,11 stroke, 10 -12 congestive heart failure, 13,14 atherosclerosis, 15 and diabetes, 16 are associated with increased plasma levels of ADMA with a decreased ratio of L-arginine to ADMA. 17 Furthermore, increased plasma ADMA is a strong independent predictor of both mortality and major nonfatal cardiovascular events in patients after myocardial infarction, coronary artery disease, and stroke. 10, 11, 18 See accompanying article on page 1462
N itric oxide (NO) exerts important biological functions 1 by stimulating guanylate cyclase to generate cGMP, 2 inhibiting mitochondrial respiration by competing with oxygen at cytochrome oxidase, 3, 4 or inducing S-nitrosylation 5 to regulate protein stability and function. NO production is restrained by the endogenous nitric oxide synthase (NOS) inhibitors asymmetrical dimethylarginine (ADMA) and N g -monomethyl-L-arginine (L-NMMA). 6, 7 In intact animals, infusion of ADMA or L-NMMA increases vascular resistance and blood pressure. 1, 8 Cardiovascular diseases, including hypertension, 9 coronary artery disease, 10, 11 stroke, 10 -12 congestive heart failure, 13, 14 atherosclerosis, 15 and diabetes, 16 are associated with increased plasma levels of ADMA with a decreased ratio of L-arginine to ADMA. 17 Furthermore, increased plasma ADMA is a strong independent predictor of both mortality and major nonfatal cardiovascular events in patients after myocardial infarction, coronary artery disease, and stroke. 10, 11, 18 See accompanying article on page 1462
Dimethylarginine dimethylaminohydrolase 1 (DDAH1) 19 and DDAH2 20 are encoded by 2 different genes. DDAH1 was initially identified as the enzyme degrading ADMA and L-NMMA. 19 Recent studies have demonstrated that loss-offunction DDAH1 mutations are associated with increases in the occurrence of coronary heart disease, thrombosis, and stroke. 10, 21 DDAH2 was also reported to have enzyme activity for degrading ADMA and L-NMMA in vitro that was similar to that of DDAH1. 20 It consequently has been assumed that in vivo metabolism of NOS inhibitors would reflect the combined abundance of both isoforms. As DDAH2 is more abundant than DDAH1 in lung, heart, and vascular endothelial cells, [22] [23] [24] it has been assumed that DDAH2 is the dominant enzyme regulating ADMA and L-NMMA in the cardiovascular system. 25 However, using an endothelialspecific DDAH1 gene-deficient mouse strain, we found that endothelial DDAH1 is important for degrading ADMA and maintaining NO bioavailability. 26 Moreover, a recent study reported that although homozygous global DDAH1 gene deletion was embryonic lethal, heterozygous DDAH1 genedeficient mice had increased tissue ADMA and decreased NO production in isolated aortic rings. 27 Thus, although there is evidence that DDAH1 contributes to vascular DDAH activity, the contribution of DDAH1 versus DDAH2 in ADMA and L-NMMA degradation in vivo has not been established.
To determine the importance of DDAH1 for in vivo metabolism of the endogenous NOS inhibitors, we generated a global DDAH1 gene-deficient (DDAH1 Ϫ/Ϫ ) mouse strain. These mice are viable, with normal growth and development, indicating that, at least in this strain, DDAH1 is not required for embryonic development. Using stable isotope-labeled ADMA or L-NMMA as a substrate, we found that ADMA and L-NMMA degradation was undetectable in all DDAH1-deficient tissues tested, even though DDAH2 expression was not altered in those tissues. These results demonstrated that DDAH1 is essential for metabolizing endogenous NOS inhibitors in vivo. Our findings help to resolve the controversy regarding the relative importance of DDAH1 and DDAH2 in degrading ADMA and L-NMMA. Namely, our data indicate that in vivo clearance of ADMA and L-NMMA is dependent on DDAH1, with no detectable role for DDAH2.
The DDAH1 Ϫ/Ϫ mice had moderate systemic hypertension and no other obvious phenotype, indicating that deficiency in DDAH activity alone is insufficient to cause structural or functional cardiovascular abnormality under unstressed conditions. The moderate hypertension in the DDAH1 Ϫ/Ϫ mice is consistent with a role for DDAH1 in modulating vascular tone and regulating blood pressure in vivo. 26, 28 This novel DDAH1 Ϫ/Ϫ mouse strain will be a valuable tool to test whether abnormal DDAH1 function will exacerbate the development of cardiovascular disease under stress conditions.
Methods

Generation of Global DDAH1
؊/؊ Mice
The DDAH1 flox/flox mice 26 were crossed with protamine (Prm)-cre mice (129-Tg(Prm-cre)58Og/J, Jackson Laboratory). The DDAH1 gene was deleted in the sperm of the male double heterozygote Prm-cre/DDAH1 flox/ϩ mice. When these male mice were crossed with wild-type female breeders, DDAH1 ϩ/Ϫ mice were generated. The homozygote global DDAH1 Ϫ/Ϫ was generated by inbreeding of the heterozygotes. Polymerase chain reaction was performed for genotyping of the offspring using primer pairs 5Ј-AAT CTG CAC AGA AGG CCC TCA A-3Ј and 5Ј-GGA GGA TCC ATT GTT ACA AGC CCT TAA CGC-3Ј for the wild-type allele and 5Ј-TGC AGG TCG AGG GAC CTA ATA ACT-3Ј and 5Ј-AAC CAC ACT GCT CGA TGA AGT TCC-3Ј for the knockout (KO) allele.
Measurement of ADMA, L-NMMA, Symmetrical Dimethylarginine, and L-Arginine Content and DDAH Activity
Tissue and plasma ADMA, L-NMMA, symmetrical dimethylarginine (SDMA), and L-arginine were measured using a high-throughput liquid chromatographic-tandem mass spectrometric method. 29 A stableisotope based technique was used for determination of DDAH activity. 30 
Small Interfering RNA Transfection
Human umbilical vein endothelial cells were transfected with DDAH1-or DDAH2-specific small interfering RNA (Santa Cruz Biotechnology). Three days after transfection, the transfection medium was removed, and the cells were incubated in EBM-2 (Lonza) for another 24 hours. Then, the medium was collected, and the amount of ADMA in the medium was determined by a validated ELISA method (DLD Diagnostika GmbH, Hamburg, Germany). 31 
Measurement of Total Nitrite and Nitrate
Osmotic Minipumps (Alzet, Charles River, Germany) containing saline or N -nitro-L-ARGININE METHYL ESTER (L-NAME; 50 mg/kg per day) 32, 33 were implanted subcutaneously in the back to deliver drug into mice for 72 hours. 34 Previous studies have demonstrated that L-NAME ranging from 33.7 to 67.4 mg/kg per day is effective in blocking NOS activity. 32, 33 Total plasma, urinary, and tissue total nitrite and nitrate (NOx) content was determined using the colorimetric assay kit from Cayman Chemical Company according to the protocol provided by the manufacturer.
Echocardiography and Measurement of Blood Pressure
Mice were anesthetized with 1.5% isoflurane. Echocardiographic images were obtained with a Visualsonics Veve 770 system as previously described. 35, 36 For aortic pressure measurement, a 1.2 Fr. pressure catheter (Scisense Inc) was introduced into the right common carotid artery and advanced into the ascending aorta. 26 L-Arginine was administrated intravenously at a dose of 400 mg/kg, a dose that has been reported to increase plasma L-arginine Ϸ2.8-fold. 37 Tail blood pressure was determined in conscious mice with the XBP 1000 system (Kent Scientific) as we previously described. 26 
Statistical Analysis
More than 5 mice from each strain were used in each assay. The Student t test was performed to compare data between groups. PϽ0.05 was considered statistically significant. Results are presented as meanϮstandard error.
Results
DDAH1
؊/؊ Mice Grow and Develop Normally
By breeding DDAH1 flox/flox mice generated in our laboratory with Prm-cre transgenic mice, we generated global heterozygous DDAH1 gene-deficient (DDAH1 ϩ/Ϫ ) mice (Figure 1a ). Cross- ϩ/Ϫ mice were generated by crossing male Prm-cre/ DDAH1 flox/ϩ to wild-type female mice (a). Genomic DNA polymerase chain reaction showed that exon 4 of DDAH1 was deleted in the DDAH1 Ϫ/Ϫ mice (b).
ing DDAH1 ϩ/Ϫ male with DDAH1 ϩ/Ϫ female mice yielded DDAH1
, and DDAH1 Ϫ/Ϫ (global DDAH1-deficient) mice at the anticipated ratios of 1:2:1. Genomic DNA polymerase chain reaction showed that exon 4 of DDAH1 was deleted from the genome of the DDAH1 Ϫ/Ϫ mice ( Figure 1b ). Both DDAH1 ϩ/Ϫ and DDAH1 Ϫ/Ϫ mice grew similarly to DDAH1 ϩ/ϩ mice up to 3 months of age. Thus, the global DDAH1 Ϫ/Ϫ mice are viable, with normal growth and development. These findings indicate that DDAH1 is not required for embryonic development in this KO strain.
؊/؊ Does Not Affect DDAH2 Expression
To determine whether DDAH1 deficiency might cause compensatory upregulation of DDAH2 expression, the protein content of DDAH2 was determined in several organs of DDAH1 Ϫ/Ϫ mice. Although DDAH1 protein was not detectable in kidney, brain, liver, lung (Figure 2a) , or other tissues from DDAH1
Ϫ/Ϫ mice, the protein levels of DDAH2 were not altered in these organs (Figure 2a and 2b) . DDAH2 mRNA content was also unchanged in tissues from the DDAH1 Ϫ/Ϫ mice (Supplemental Figure I , available online at http://atvb.ahajournals.org). DDAH1 Ϫ/Ϫ had no significant effect on the expression of endothelial NOS, protein arginine methyltransferase-1, protein arginine methyltransferase-3, or cationic amino acid transporter in brain, kidney, lung (Supplemental Figure II ), and other tissues tested.
ADMA Degradation Was Not Detectable in Tissues From DDAH1
؊/؊ Mice Normal tissues continuously generate ADMA. To avoid interference from endogenous ADMA, we performed the DDAH activity assay using stable isotope-labeled ADMA as a substrate. Enzyme activity for degrading ADMA was undetectable in all tested tissues from the DDAH1 Ϫ/Ϫ mice (Figure 2c ), indicating that DDAH1 is responsible for the majority, if not all, of enzyme activity for metabolizing ADMA in these tissues.
L-NMMA Degradation Was Not Detectable in Tissues From DDAH1
؊/؊ Mice Because DDAH1 and DDAH2 might have different substrate preferences, we went on to determine the effect of DDAH1 deficiency on L-NMMA degradation. Using stable isotopelabeled d6-L-NMMA as substrate, we found that the activity for metabolizing L-NMMA was also abolished in all tissues tested from the DDAH1 Ϫ/Ϫ mice (Figure 2d ). Because DDAH2 expression was not changed in the DDAH1 Ϫ/Ϫ mice, these results indicate that DDAH2 did not have a detectable contribution in the degradation of L-NMMA in these tissues.
DDAH1
؊/؊ Caused Accumulation of Tissue ADMA and L-NMMA ADMA and L-NMMA tissue content in kidney, brain, and lung was significantly increased in the global DDAH1 Ϫ/Ϫ mice as compared with DDAH1 ϩ/ϩ mice (Figure 3a to 3c) , indicating that DDAH1 is pivotal in regulating tissue ADMA and L-NMMA levels. Because tissue L-arginine and SDMA were not different between DDAH1
Ϫ/Ϫ and DDAH1 ϩ/ϩ mice, the ratios of L-arginine to ADMA and to L-NMMA, indicators of systemic nitric oxide bioavailability, 17 were significantly decreased in these organs (Figure 3a to 3c) . In addition, the ADMA content of mesenteric microvessels was significantly increased in DDAH1 Ϫ/Ϫ mice (64.0 nmol/g protein in DDAH1 Ϫ/Ϫ versus 31.7 nmol/g protein in wild-type mice, PϽ0.05). Total NOx in mesenteric vessels was significantly decreased in DDAH1 Ϫ/Ϫ mice (Supplemental Figure III) .
؊/؊ Caused Accumulation of Plasma ADMA and L-NMMA and Their Ratios to L-Arginine
Ϫ/Ϫ caused significant increases of plasma ADMA and L-NMMA (Figure 4a and 4b) but had no effect on plasma Ϫ/Ϫ mice revealed that DDAH1 is essential for degradation of ADMA and L-NMMA. DDAH1 Ϫ/Ϫ abolished DDAH1 protein expression in all tissues tested (a) but had no effect on DDAH2 protein expression (b). DDAH1
Ϫ/Ϫ abolished DDAH activity in kidney, brain, and lung as tested using either stable isotope-labeled d6-ADMA (c) or d6-L-NMMA as substrate (d). *PϽ0.05 compared with samples from wild-type littermates.
L-arginine or SDMA (Figure 4c and 4d) . As a result, DDAH1 gene deletion caused significant decreases in the ratios of L-arginine to ADMA or L-NMMA in plasma (Figure 4e and  4f) . Thus, DDAH1 metabolizes ADMA and L-NMMA in tissue and also clears these NOS inhibitors from the circulation, indicating that DDAH1 acts to maintain systemic homeostasis of the endogenous NOS inhibitors.
DDAH1 ؊/؊ Decreased NO Production and Increased Blood Pressure
To determine the impact of DDAH1 Ϫ/Ϫ on systemic NO production, total NOx were measured in urine and plasma from fasting mice drinking deionized water. Both urinary and plasma NOx content were significantly decreased in the DDAH1 Ϫ/Ϫ mice, implying that accumulation of NOS inhibitors in the DDAH1 KO mice inhibited NOx generation. (Figure 4g and 4h) . The NOS inhibitor L-NAME decreased urinary and plasma NOx in both DDAH1
Ϫ/Ϫ and wild-type mice. After L-NAME, the difference of urinary NOx content between DDAH1 Ϫ/Ϫ and wild-type mice was no longer statistically significant, and the difference of plasma NOx content between DDAH1 Ϫ/Ϫ and wild-type mice was reduced. Of note, approximately 40% of both urine and plasma NOx content remained after L-NAME, consistent with previous reports that NOx was also generated by non-NOS sources. DDAH1 Ϫ/Ϫ also significantly decreased acetylcholine-induced NO generation by aortic rings (Figure 4i ). Previous studies have demonstrated that infusion of ADMA or L-NMMA causes vasoconstriction in vivo. 8 Consistent with this, we found that the increased levels of ADMA and L-NMMA in the DDAH1 Ϫ/Ϫ mice were associated with a moderate significant increase of tail blood pressure measured in the awake state (Figure 4j ), as well as direct catheter measurement of aortic pressure (Figure 4k ). The moderate increase of blood pressure in DDAH1 Ϫ/Ϫ mice was similar to the increase of blood pressure in our endothelial-specific DDAH1 Ϫ/Ϫ mice 26 and in global endothelial NOS Ϫ/Ϫ mice. 38 We also determined ADMA clearance by mesenteric microvessels from wild-type mice and DDAH1 Ϫ/Ϫ mice. ADMA degradation was undetectable in mesenteric vessels from DDAH1 Ϫ/Ϫ mice (data not shown). The elevated blood pressure in the DDAH1 Ϫ/Ϫ mice was normalized by infusion of L-arginine at a dose of 400 mg/kg (Supplemental Figure IV) . 37 
DDAH1
؊/؊ Had No Effect on the Structure of the Kidney, Lung, or Heart DDAH1 Ϫ/Ϫ had no evident effect on the gross or histological appearance of the kidneys, lung, or heart. In addition, left ventricular dimensions and function were unchanged in DDAH1 Ϫ/Ϫ mice (Table) .
Selective Gene Silencing of DDAH1 but Not DDAH2 Caused ADMA Accumulation in Cultured Human Umbilical Vein Endothelial Cells
We also determined the effect of selective gene silencing of DDAH1 and DDAH2 on ADMA accumulation in human umbilical vein endothelial cells using specific small interfering RNA. DDAH1 gene silencing decreased DDAH1 expression Ϸ80% and significantly increased the ADMA level in the culture medium. DDAH2 gene silencing abolished DDAH2 expression but had no detectable effect on ADMA content in the culture medium (Supplemental Figure V) . This result is consistent with previous reports that selective DDAH2 gene silencing had no effect on ADMA content in cultured bovine aortic endothelial cells 39 or in rats. 40 
Discussion
The new findings of this study are as follows: (1) a strain of viable DDAH1 Ϫ/Ϫ mice was developed that grow and develop normally; (2) DDAH1 Ϫ/Ϫ caused accumulation of ADMA and L-NMMA in plasma and tissue; (3) DDAH1 Ϫ/Ϫ had no effect on DDAH2 expression in any tissue tested; (4) tissue DDAH activity for ADMA and L-NMMA was not detectable in any tissues tested from the DDAH1 Ϫ/Ϫ mice; and (5) DDAH1
Ϫ/Ϫ resulted in moderate hypertension. These findings indicate that DDAH1 is essential for degrading ADMA and L-NMMA in vivo but is not essential for embryonic development in this KO strain. Moreover, we failed to detect a role for DDAH2 in degrading ADMA or L-NMMA, a finding that helps to resolve the controversy regarding DDAH1 and DDAH2 in degrading the NOS inhibitors. The accumulation of ADMA and L-NMMA in plasma and tissues of DDAH1 Ϫ/Ϫ mice is similar to our findings in endo-DDAH1 Ϫ/Ϫ mice. 26 The decreased ratios of L-arginine to ADMA or L-NMMA, the decreases in urinary and plasma NOx in the DDAH1 Ϫ/Ϫ mice and the decreased NO generation by aortic rings in response to acetylcholine establish an important role for DDAH1 in maintaining systemic and tissue NO bio- Ϫ/Ϫ mice. DDAH1 Ϫ/Ϫ increased ADMA (a) and L-NMMA (b) content in plasma but had no effect on plasma L-arginine (c) and SDMA (d) levels. The ratios of L-arginine to ADMA (e) and L-NMMA (f) in the DDAH1 Ϫ/Ϫ were significantly decreased. Total NOx in the urine and plasma of DDAH1 Ϫ/Ϫ mice were also significantly decreased; L-NAME caused further decreases in NOx, but Ϸ40% of both urinary and plasma NOx was resistant to NOS inhibition with L-NAME (g, h). DDAH1 Ϫ/Ϫ decreased acetylcholine (Ach)-induced NO generation in aortic rings (i) and increased blood pressure (j and k). *PϽ0.05 compared with corresponding wild-type controls, #PϽ0.05 compared with saline-treated controls. DAF2 indicates, 4,5-diaminofluoresceine diacetate; F/F 0 , relative fluorescence signal intensity.
availability. The moderate increase of blood pressure in the DDAH1 Ϫ/Ϫ mice implies that chronic accumulation of endogenous NOS inhibitors results in constriction of the resistance vessels where blood pressure is controlled and is in agreement with the loss of DDAH activity in mesenteric resistance vessels.
The stable isotope-labeled ADMA or L-NMMA technique represents the most reliable method for DDAH activity analysis. 30 Using stable isotope-labeled ADMA or L-NMMA as substrate, DDAH activity was essentially undetectable in lung and kidney from the DDAH1 Ϫ/Ϫ mice, despite the fact that DDAH2 was highly expressed (and unchanged as compared with wild-type mice). Because DDAH2 is highly abundant in many of these tissues, the findings imply that DDAH2 does not contribute to the degradation of ADMA or L-NMMA. Future studies using global DDAH2 KO mice will be useful to further explore the physiological role of DDAH2 in ADMA degradation.
The fold increase in tissue ADMA and L-NMMA was less in the kidney than in other tissues, suggesting the possibility that another pathway might contribute to their clearance. Previous studies have reported that ADMA can be metabolized through an alternate pathway by alanine-glyoxylate aminotransferase 2 (AGXT2), a mitochondrial aminotransferase expressed primarily in the kidney. 41 Rodionov et al 42 demonstrated that overexpression of AGXT2 using an adenoviral expression vector caused decreased ADMA levels in the plasma and liver of C57BL/6 mice. However, when rats were injected with radiolabeled ADMA, transamination products of ADMA were detected in the urine, but most of the radioactivity appeared as citrulline, implying that ADMA was metabolized principally by DDAH. 43 In agreement with that report, the disappearance of radioisotopelabeled ADMA and L-NMMA was nearly undetectable in kidney tissue from our DDAH1 Ϫ/Ϫ mice, implying that DDAH1 was principally responsible for ADMA and L-NMMA degradation in the kidney. Our data suggests that AGXT2 is likely to make a minimal direct contribution to ADMA degradation. A likely cause for the relatively smaller increase of ADMA and L-NMMA in kidney tissue of DDAH1 Ϫ/Ϫ mice may relate to its capacity to directly excrete ADMA and L-NMMA into the urine.
Our finding that DDAH1 Ϫ/Ϫ mice developed and grew comparably to DDAH1 ϩ/ϩ mice indicates that DDAH1 is not essential for embryonic development in this KO strain. In addition, Lexicon Pharmaceuticals, Inc, has recently generated a viable global DDAH1 KO strain. These findings are in contrast to a previous study in which DDAH1
Ϫ/Ϫ was reported to be embryonic lethal. 27 The DNA construct used in the previous study was designed to delete exon 1 of DDAH1, whereas exon 4 was targeted in our study. Study of embryonic development in the previous global DDAH1 Ϫ/Ϫ strain showed that only Ϸ5% of blastocysts were DDAH1
Ϫ/Ϫ at embryo day 2, 44 suggesting that the developmental defects in those homozygotes occurred before implantation. Because triple endothelial NOS/inducible NOS/neuronal NOS-null mice are reported to be viable, 45 the lethality of the previous DDAH1 Ϫ/Ϫ strain is not likely due to NO-dependent implantation or placentation defects. It is possible that some important genomic sequence that is critical for embryonic development was disrupted in the previous study so that the embryonic stem cells used to generate their DDAH1 Ϫ/Ϫ strain had defects that contributed to the lethality. 27 In summary, the present data demonstrate that DDAH1 is essential for degrading ADMA and L-NMMA in vivo but is not required for embryonic development in this DDAH1 Ϫ/Ϫ strain. Our data fail to support an important physiological role for DDAH2 in metabolizing ADMA and L-NMMA. Impaired DDAH1 function caused a moderate increase of blood pressure similar to that in endothelial NOS gene-deficient mice 38 and in our endothelial specific DDAH1-deficient mice. 26 This novel DDAH1 Ϫ/Ϫ mouse strain will be a valuable tool to test whether abnormal DDAH1 function will exacerbate the development of cardiovascular pathology under stress conditions.
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